Psyence BioMed invests up to $5M in PsyLabs, forms Texas unit

Go back to Psyence BioMed invests up to $5M in PsyLabs, forms Texas unit

Psyence BioMed Announces Strategic Ibogaine Investment

September 23, 2026 7:00 AM EDT

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange

Highlights

The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD).Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.Psyence BioMed has agreed to invest up to US$5 million in PsyLabs, of which US$2.4 million has been committed, to support scientific development and pharmaceutical-grade... More